Home › Compare › FRTX vs EQR

FRTX vs EQR: Dividend Comparison 2026

FRTX yields 213.90% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FRTX wins by $177.04M in total portfolio value
10 years
FRTX
FRTX
● Live price
213.90%
Share price
$0.94
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$177.09M
Annual income
$92,250,740.75
Full FRTX calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — FRTX vs EQR

📍 FRTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRTXEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRTX + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
FRTX pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRTX
Annual income on $10K today (after 15% tax)
$18,181.82/yr
After 10yr DRIP, annual income (after tax)
$78,413,129.64/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, FRTX beats the other by $78,408,475.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRTX + EQR for your $10,000?

FRTX: 50%EQR: 50%
100% EQR50/50100% FRTX
Portfolio after 10yr
$88.57M
Annual income
$46,128,108.17/yr
Blended yield
52.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

FRTX
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-18.7
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRTX buys
0
EQR buys
0
No recent congressional trades found for FRTX or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRTXEQR
Forward yield213.90% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$177.09M ✓$47.8K
Annual income after 10y$92,250,740.75 ✓$5,475.61
Total dividends collected$167.49M ✓$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: FRTX vs EQR ($10,000, DRIP)

YearFRTX PortfolioFRTX Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$32,090$21,390.37$11,380$679.82+$20.7K → FRTX
2$98,489$64,151.88$13,014$837.25+$85.5K → FRTX
3$289,391$184,008.00$14,961$1,036.20+$274.4K → FRTX
4$814,951$505,302.85$17,297$1,289.22+$797.7K → FRTX
5$2,201,885$1,329,887.07$20,121$1,613.15+$2.18M → FRTX
6$5,714,120$3,358,103.33$23,561$2,030.84+$5.69M → FRTX
7$14,258,620$8,144,511.98$27,783$2,573.54+$14.23M → FRTX
8$34,250,418$18,993,694.31$33,013$3,284.39+$34.22M → FRTX
9$79,287,637$42,639,690.06$39,547$4,223.51+$79.25M → FRTX
10$177,088,513$92,250,740.75$47,791$5,475.61+$177.04M → FRTX

FRTX vs EQR: Complete Analysis 2026

FRTX — Stock

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Full FRTX Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this FRTX vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRTX vs SCHDFRTX vs JEPIFRTX vs OFRTX vs KOFRTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.